Bioxcel Therapeutics earnings were -$40.1M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest BTAI earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$7.3M, down 33.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BTAI reported annual earnings of -$59.6M, with -66.7% growth.
Bioxcel Therapeutics Earnings Reports & History FAQ
What were Bioxcel Therapeutics's earnings last quarter?
On BTAI's earnings call on Invalid Date, Bioxcel Therapeutics (NASDAQ: BTAI) reported Q1 2025 earnings per share (EPS) of -$1.50, up 89.2% year over year. Total BTAI earnings for the quarter were -$7.25 million. In the same quarter last year, Bioxcel Therapeutics's earnings per share (EPS) was -$13.89.
Is Bioxcel Therapeutics profitable or losing money?
As of the last Bioxcel Therapeutics earnings report, Bioxcel Therapeutics is currently losing money. Bioxcel Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$40.06 million, a 73.82% decrease year over year.
What was BTAI's earnings growth in the past year?
As of Bioxcel Therapeutics's earnings date in Invalid Date, Bioxcel Therapeutics's earnings has grown year over year. BTAI earnings in the past year totalled -$40.06 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.